Xenotransplantation

Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024

Retrieved on: 
Monday, April 8, 2024
PARP1, Chem, MDA, Drug, Patient, Cancer, IND, Abstract, AACR, Survivor, DRF, Clinical trial, PARP, MOA, Xenotransplantation, Safety, Biology, San Diego Convention Center, Drug discovery, Medicine, Annual general meeting, PCC, Pharmaceutical industry

"After advancing LAE102, our internally discovered antibody against ActRIIA, into IND stage, Laekna continues to strengthen our internal discovery efforts, with new drug candidates emerging", said Dr. Justin Gu, Chief Scientific Officer of Laekna.

Key Points: 
  • "After advancing LAE102, our internally discovered antibody against ActRIIA, into IND stage, Laekna continues to strengthen our internal discovery efforts, with new drug candidates emerging", said Dr. Justin Gu, Chief Scientific Officer of Laekna.
  • Laekna will continue our internal effort of discovery novel drug candidates to provide more options for patients."
  • The company has internally discovered 14 drug candidates, among which seven have been optimized and advanced to PCC (pre-clinical candidate) stage.
  • The Annual Meeting of AACR is set for April 05 to 10, 2024 at the San Diego Convention Center, California, USA.

United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

Retrieved on: 
Tuesday, March 26, 2024
Research, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, FRS, Gene editing, Acute liver failure, New product development, UTHR, Patient, United Therapeutics, Lung, Xenotransplantation, Manuscript, MBBS, Regenerative medicine, PBC, Clinical trial, Therapy, Heart, Creativity, Physiology, Kidney, FACS, FRCS, Liver, Physiological Reviews, Food, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.
  • Beyond xenotransplantation, United Therapeutics has six other organ manufacturing programs in the lung, kidney, and liver using three distinct platforms: regenerative medicine, bio-artificial organs, and 3-D organ printing.
  • United Therapeutics believes that this study will be the first human clinical trial of a manufactured organ.
  • At United Therapeutics, our vision and mission are one.

eGenesis Announces Publication in Nature of Landmark Preclinical Data Demonstrating Long-Term Survival with Genetically Engineered Porcine Kidneys

Retrieved on: 
Wednesday, October 11, 2023
Xenotransplantation, Engineering, Biomarker, Hope, Inflammation, Genome, Endothelium, Risk, Data, Massachusetts General Hospital, Survival, Coagulation, Transplant, Hospital, Patient, Organ dysfunction, Pelvic floor dysfunction, Gene, Harvard Medical School, Transgene, NHP, Human, Filtration, Vaccine, Dentistry, Nature

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible (HuCo™) organs for the treatment of organ failure, today announced publication in the journal Nature of long-term survival data from a proof-of-concept study evaluating engineered porcine donor kidneys transplanted into a cynomolgus macaque model. This dataset will support advancement of the company’s lead candidate for kidney transplant, EGEN-2784, toward clinical development.

Key Points: 
  • These results represent the largest and most comprehensive preclinical dataset published in the field to date.
  • Recipient survival in the preclinical setting has historically been measured in weeks or months.
  • The publication titled: “ Design and Testing of a Humanized Porcine Donor for Xenotransplantation ,” reported long-term survival of NHP recipients of the company’s genetically engineered porcine kidneys.
  • “At eGenesis, we are focused on transformational progress for the field – improving long-term survival for transplant recipients from months to years,” said Michael Curtis, Ph.D., Chief Executive Officer of eGenesis.

NanoString Platforms Advance Groundbreaking Studies of Immune Response in Pig-to-Human Organ Transplants

Retrieved on: 
Monday, August 21, 2023
Health, Surgery, Genetics, Other Science, Research, Science, Biotechnology, Xenotransplantation, Human, Allo, University, Paris Institute for Advanced Study, University of Paris, Neutrophil, Doctor of Philosophy, Macrophage, The Wall Street Journal, NYU, Hope, DRS, NK, Brain death, Transplant, System, Monocyte, Animal, MD, Patient, The New York Times, Organ transplantation, Kidney, NanoString Technologies, Medical research, Vaccine, Dentistry, Lancet

The groundbreaking study featured in the August issue and an accompanying commentary of The Lancet medical journal produced fundamental new data on the first pig-to-human organ transplants.

Key Points: 
  • The groundbreaking study featured in the August issue and an accompanying commentary of The Lancet medical journal produced fundamental new data on the first pig-to-human organ transplants.
  • Scientists used the nCounter Human Organ Transplant Panel , a process NanoString developed with the Banff International Classification Consortium.
  • The GeoMx Digital Spatial Profiler was used next to isolate the immune response to specific regions of the kidney.
  • “We congratulate Dr. Loupy and his extended team on their findings and celebrate the on-going successful studies in humans.”

eGenesis Presents New Data on Long-Term Survival in Preclinical Kidney Xenotransplantation at American Transplant Congress 2023

Retrieved on: 
Monday, June 5, 2023
Xenotransplantation, Thrombotic microangiopathy, Tissue, Survivor, TGS, ATI, DNA, Immunology, Serum, Biotechnology, Gene editing, Survival, AMR, Cell, Antibody, Doctor of Philosophy, TG, Research, DSA, Harvard Medical School, Transplant, Chemistry, Sera, Protein, Public, Animal, MD, Plasma, Risk, Coagulation, Filtration, Hospital, ATC, Hokkaido University, SLA, Health, Safety, Pelvic floor dysfunction, Postdoctoral researcher, TMA, Medical device, Dentistry, Vaccine, Dietary supplement, Primate

CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, will present new data during the American Transplant Congress (ATC) 2023, held June 3 – June 7, 2023 in San Diego, CA.

Key Points: 
  • CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs for the treatment of organ failure, will present new data during the American Transplant Congress (ATC) 2023, held June 3 – June 7, 2023 in San Diego, CA.
  • “The data we are presenting at ATC 2023 demonstrate eGenesis’ continued leadership in the field of xenotransplantation,” said Mike Curtis, Ph.D., CEO of eGenesis.
  • Oral Presentation: Genetically Modified Porcine Kidneys Expressing Human Transgenes Support >2-year Survival in Porcine Donor to Cynomolgus Macaque Recipient Xenotransplantation.
  • eGenesis scientists genetically engineered porcine donors to remove three known xenoantigens implicated in hyperacute rejection.

Karius and eGenesis partner to help accelerate xenotransplantation for patients in need of organ transplants

Retrieved on: 
Tuesday, April 11, 2023
Infection, DNA, Human, Partnership, Biotechnology, Liquid biopsy, Cell, Transplant, M.D, Patient, Risk, Primate, The New England Journal of Medicine, Diagnosis, AI, Safety, Pelvic floor dysfunction, Genome, Vaccine, Medicine, Loris Karius, Xenotransplantation

REDWOOD CITY, Calif. and CAMBRIDGE, Mass., April 11, 2023 /PRNewswire/ -- Karius®, the world leader in liquid biopsy for infectious diseases, and eGenesis, Inc. a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced a partnership through which the two companies will develop infectious disease diagnostics for xenotransplantation initially from porcine to primates and ultimately to humans. Through the partnership, Karius will leverage its platform to power the detection and quantification of pathogens with potential to occur in porcine organ donors.

Key Points: 
  • Through the partnership, Karius will leverage its platform to power the detection and quantification of pathogens with potential to occur in porcine organ donors.
  • Karius and eGenesis will collaborate in the development of this expanded platform and plan to complete this work by early 2024.
  • An estimated 6,000 of these patients will die each year before they receive an organ transplant1.
  • "The expansion into infectious disease diagnostics in xenotransplantation provides another proof point for our platform's plasticity through data and AI."

Researchers confirm successful rehabilitation and recovery of human donor lungs previously deemed unfit for transplant

Retrieved on: 
Monday, January 23, 2023
Vanderbilt University Medical Center, Xenotransplantation, Lung transplantation, State university system, Stanford University, SUNY Downstate Medical Center, Transplant, Surgeon, The Journal of Heart and Lung Transplantation, Hospital, Columbia University, Surgery, Vanderbilt University, Patient, Rehabilitation, Journal, Medical device, Heart

NEW YORK, Jan. 23, 2023 /PRNewswire/ -- A novel method for supporting and recovering donor lungs outside the body shows potential to increase the number of organs available for transplant, according to a recent study published in The Journal of Heart and Lung Transplantation.

Key Points: 
  • The organ shortage crisis is increasingly dire, as thousands of patients die every year waiting to receive donor organs.
  • Despite urgent demand, nearly 80% of donated lungs are too damaged for transplantation, often due to reversible conditions.
  • A promising approach to alleviate the organ shortage involves rehabilitation and recovery of these unutilized donor organs.
  • Results of the study "Technique for xenogeneic cross-circulation to support human donor lungs ex vivo" are reported in The Journal of Heart and Lung Transplantation , and further confirm the efficacy of the technique to rehabilitate human donor lungs initially deemed unfit for transplantation.

ISHLT Presents Xenotransplantation Webinar on 25 May

Retrieved on: 
Monday, May 2, 2022
Linda, Xenotransplantation, Pandemic, EDT, Population, Transplant, CA, Patient, Lung transplantation, Final Frontier, Attention, Solution, Hospital, Risk, MD, Education, Infection, International Society for Heart and Lung Transplantation, International Society, Research, Annual general meeting, Multimedia, Medical device, Dentistry, Pharmaceutical industry, Medicine

CHICAGO, May 2, 2022 /PRNewswire/ -- The International Society for Heart and Lung Transplantation (ISHLT) will follow the xenotransplantation presentation from its Annual Meeting opening plenary session with an in-depth xenotransplantation webinar, 25 May at noon EDT on ISHLTv , the online education platform for the international heart and lung transplantation community.

Key Points: 
  • CHICAGO, May 2, 2022 /PRNewswire/ -- The International Society for Heart and Lung Transplantation (ISHLT) will follow the xenotransplantation presentation from its Annual Meeting opening plenary session with an in-depth xenotransplantation webinar, 25 May at noon EDT on ISHLTv , the online education platform for the international heart and lung transplantation community.
    "
  • "Xenotransplantation has received a surge of attention in the media recently," said Dr. Urschel.
  • All registrants will receive on-demand access to the webinar to view it any time after the live presentation.
  • With members in more than 50 countries, ISHLT is the world's largest organization dedicated to the research, education and advocacy of end-stage heart and lung disease.

Makana™ Therapeutics Announces Relocation of Its Corporate Headquarters to Miami

Retrieved on: 
Thursday, April 7, 2022
Biotechnology, Surgery, Other Health, Health, Cardiology, Cell, Therapy, University, Gene, Miniature pig, Xenotransplantation, Immunosuppression, Genetics, Jackson Memorial Hospital, MTI, Doctor of Philosophy, TKO, Tissue, Communication, Â, Kidney transplantation, Animal, FACS, Dentistry, MD

Makana Therapeutics, a global leader in the field of xenotransplantation, announced today that it has relocated its corporate headquarters to Miami, Florida from Eagan, Minnesota.

Key Points: 
  • Makana Therapeutics, a global leader in the field of xenotransplantation, announced today that it has relocated its corporate headquarters to Miami, Florida from Eagan, Minnesota.
  • The move enables closer synergy with the Miami Transplant Institute (MTI), a collaboration between Jackson Memorial Hospital and the University of Miami Health System.
  • The xenotransplant program at MTI is led by Joe Tector, MD, PhD, FACS, who is also the founder of Makana.
  • Platt said moving the companys corporate headquarters to Miami streamlines communication and collaboration with researchers at the xenotransplant program at MTI.

CareDx Leads the Way in Xenotransplant Organ Surveillance in Monitoring World’s First Successful Living Xenotransplantation

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, Program, Maryland School, Gene expression profiling, University of Maryland Medical Center, University, Science, Annual report, Xenotransplantation, Transplant, Heart, Surgeon, Precision medicine, DNA, Caregiver, University of Maryland School of Medicine, SAN, Nasdaq, Patient, Solution, CEO, SEC, Dentistry

As an innovator in organ transplant surveillance, CareDx is proud to be working with UMSOM on this landmark case which represents a groundbreaking moment in the history of transplantation, said Reg Seeto, CEO and President of CareDx.

Key Points: 
  • As an innovator in organ transplant surveillance, CareDx is proud to be working with UMSOM on this landmark case which represents a groundbreaking moment in the history of transplantation, said Reg Seeto, CEO and President of CareDx.
  • Its incredibly rewarding to apply our years of experience and dedication to the transplant community by offering the worlds first biomarker surveillance solution for xenotransplantation.
  • CareDx has served over 80,000 organ transplant patients with its AlloSureor AlloMap assays for their post-transplant care.
  • CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.